Table 6.
Antifracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomised controlled trials. (Updated from [42, 43])
| Effect on vertebral fracture risk | Effect on non-vertebral fracture risk | |||
|---|---|---|---|---|
| Osteoporosis | Established osteoporosisa | Osteoporosis | Established osteoporosisa | |
| Alendronate | + | + | NA | + (including hip) |
| Risedronate | + | + | NA | + (including hip) |
| Ibandronate | NA | + | NA | +b |
| Zoledronic acid | + | + | NA | NA (+)c |
| HRT | + | + | + | + |
| Raloxifene | + | + | NA | NA |
| Teriparatide and PTH | NA | + | NA | + |
| Strontium ranelate | + | + | +(including hip) | + (including hip) |
NA: no evidence available
+: effective drug
aWomen with a prior vertebral fracture
bIn subsets of patients only (post-hoc analysis)
cMixed group of patients with or without prevalent vertebral fractures